Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2016', provides in depth analysis on Gamma Secretase (EC 3.4.23.) targeted pipeline therapeutics. 

The report provides comprehensive information on the Gamma Secretase (EC 3.4.23.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)
- The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Gamma Secretase (EC 3.4.23.) Overview 8
Therapeutics Development 9
Gamma Secretase (EC 3.4.23.) - Products under Development by Stage of Development 9
Gamma Secretase (EC 3.4.23.) - Products under Development by Therapy Area 10
Gamma Secretase (EC 3.4.23.) - Products under Development by Indication 11
Gamma Secretase (EC 3.4.23.) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Gamma Secretase (EC 3.4.23.) - Products under Development by Companies 14
Gamma Secretase (EC 3.4.23.) - Products under Development by Universities/Institutes 16
Gamma Secretase (EC 3.4.23.) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Gamma Secretase (EC 3.4.23.) - Companies Involved in Therapeutics Development 23
Amgen Inc. 23
Astellas Pharma Inc. 24
Bristol-Myers Squibb Company 25
Critical Outcome Technologies Inc. 26
FORUM Pharmaceuticals Inc. 27
Lipopharma Therapeutics SL 28
Merck & Co., Inc. 29
NeuroGenetic Pharmaceuticals, Inc. 30
Pfizer Inc. 31
Stemline Therapeutics, Inc. 32
Sumitomo Dainippon Pharma Co., Ltd. 33
Takeda Pharmaceutical Company Limited 34
Gamma Secretase (EC 3.4.23.) - Drug Profiles 35
AS-2715348 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
BMS-932481 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
BMS-986133 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
GSI-34 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
LP-226A1 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
MK-0752 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
MRK-003 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
NGP-328 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
NGP-555 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
nirogacestat - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
SL-301 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
SL-302 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Small Molecules to Inhibit Ap1B Gamma-Secretase for Alzheimer's Disease - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Gamma Secretase (EC 3.4.23.) - Dormant Projects 60
Gamma Secretase (EC 3.4.23.) - Discontinued Products 63
Gamma Secretase (EC 3.4.23.) - Featured News & Press Releases 65
Nov 10, 2015: NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer's Disease; Reports Initial Results of Phase 1a Clinical Trial 65
Sep 29, 2014: FDA Approves NeuroGenetic Pharmaceuticals Application to Begin Clinical Trials for Its NGP 555 Compound to Treat and Prevent Alzheimer's Disease 65
Jul 15, 2011: NeuroGenetic Pharma Receives SBIR Grant For Preclinical Development And IND Application Of NGP 555 To Treat Alzheimer's Disease 65
Jul 21, 2009: Critical Outcome Technologies Inc. Announces the Launch of a Drug Discovery Program for Alzheimer's disease 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by Amgen Inc., H2 2016 23
Pipeline by Astellas Pharma Inc., H2 2016 24
Pipeline by Bristol-Myers Squibb Company, H2 2016 25
Pipeline by Critical Outcome Technologies Inc., H2 2016 26
Pipeline by FORUM Pharmaceuticals Inc., H2 2016 27
Pipeline by Lipopharma Therapeutics SL, H2 2016 28
Pipeline by Merck & Co., Inc., H2 2016 29
Pipeline by NeuroGenetic Pharmaceuticals, Inc., H2 2016 30
Pipeline by Pfizer Inc., H2 2016 31
Pipeline by Stemline Therapeutics, Inc., H2 2016 32
Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 33
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 34
Dormant Projects, H2 2016 60
Dormant Projects (Contd..1), H2 2016 61
Dormant Projects (Contd..2), H2 2016 62
Discontinued Products, H2 2016 63
Discontinued Products (Contd..1), H2 2016 64